What is Halozyme Therapeutics Price-to-Free-Cash-Flow?
As of today (2024-04-27), Halozyme Therapeutics's share price is $38.57.
Halozyme Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.79. Hence, Halozyme Therapeutics's Price-to-Free-Cash-Flow Ratio for today is 13.83.
The historical rank and industry rank for Halozyme Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
HALO'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.08 Med: 21.83 Max: 137.3
Current: 13.84
During the past 13 years, Halozyme Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 137.30. The lowest was 12.08. And the median was 21.83.
HALO's Price-to-Free-Cash-Flow is ranked better than 76.64% of 214
companies
in the Biotechnology industry
Industry Median: 30.52
vs HALO: 13.84
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Halozyme Therapeutics was 66.30% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 95.20% per year.
During the past 13 years, Halozyme Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 95.20% per year. The lowest was -180.60% per year. And the median was -6.60% per year.
Halozyme Therapeutics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Halozyme Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Halozyme Therapeutics's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Halozyme Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Price-to-Free-Cash-Flow falls into.
Halozyme Therapeutics's Share Price of today is $38.57. Halozyme Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.79.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Halozyme Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 